Basic – suitable for anyone, no matter what their background
Intermediate – ideal for research nurses, clinical nurse specialists, administrative staff, clinical trials coordinators
Intermediate/advanced – suitable for experienced research nurses and trials staff, or anyone involved in cancer who understands concepts such as DNA, chromosomes, genes, the cell cycle
Advanced – ideal for pharmacists, scientifically-minded nurses, pharmaceutical companies, junior doctors
General courses on cancer biology and targeted cancer treatments:
1 Cancer, biology, treatments and trials: A guide for consumers (2 day)
Description: This course provides a broad grounding in cancer cell biology, including key concepts such as cells, DNA, proteins, cell division, gene transcription, genetic mutations, cell communication and cancer growth and metastasis. It gives an overview of standard cancer treatments and an introduction to the concepts behind targeted cancer treatments. Also includes an overview of drug development and clinical trials.
2 Cancer biology and targeted treatments: demystifying the science (1 day)
Description: This course gives cancer nurses and trials staff the knowledge and confidence to discuss targeted cancer treatments with patients and colleagues. The focus of the day is on cancer biology and the science behind licensed treatments for solid tumours, including monoclonal antibodies, small molecule kinase inhibitors and immunotherapies.
3 Cancer biology & personalised treatments for solid tumours (2 day)
Description: This course provides a grounding in cancer biology and genetics before moving to descriptions of a wide range of targeted treatments for solid tumours. Also includes mechanisms of drug resistance and an introduction to biomarkers and personalised cancer care. Uses a variety of practical exercises, question sheets and quizzes.
4 The science of targeted cancer treatments (1 day)
Description: This course is used by research networks and clinical trials units for their more senior staff. As well as an overview of targeted treatments against receptor tyrosine kinases, B-Raf, MEK, mTOR, angiogenesis etc. it also includes the concepts behind cancer immunotherapy. It also discusses clinical trial design and the use of biomarkers
5 Cancer biology & the science of targeted cancer treatments (2 day)
Description: Similar to course 3, but requires delegates to have some prior understanding of cancer cell biology. Includes an introduction to targeted treatments for haematological cancers.
6 Molecular mechanisms of targeted cancer treatments (1 day)
Description: This course covers a wide range of licensed and experimental cancer treatments, explaining their biological mechanism of action at a molecular and cellular level. It also contains detailed information on mechanisms of drug resistance and discusses the future of personalised cancer medicine.
7 Malignant melanoma and beyond: An introduction to targeted treatments and cancer immunotherapy (1 day)
Description: This course describes the recent advances made targeted treatments for cancer, using malignant melanoma as the primary example. Delegates will learn about the faulty genes, pathways and proteins that drive malignant melanoma and other solid tumours, and the mechanism of action of targeted treatments such as B-Raf and MEK inhibitors and immunotherapy.
8 Targeted treatments for breast cancer (1 day)
Description: This study day provides an overview of the cellular and genetic makeup of breast cancer and explains the science behind targeted treatments in use and in development. Includes an overview of hormone treatments and chemotherapy as well as HER2-targeted treatments and CDK4/6 inhibitors. Novel strategies for triple-negative cancers are discussed, such as PARP inhibitors and immunotherapy.
9 Targeted cancer treatments for breast and ovarian cancer (1 day or 2 half-days)
Description: This course provides an overview of the cellular and genetic makeup of breast and ovarian cancer, along with information on targeted treatments in use and in development for these cancers. It includes treatments such as HER2-inhibitors, PARP inhibitors, angiogenesis inhibitors, checkpoint inhibitors and an overview of hormone treatments and the logic behind various treatment combinations.
10 Targeted treatments for cancers of the blood (1 day or 2 half-days)
Description: This course introduces the unique cellular and genetic features of haematological cancers. It covers a range of targeted treatment approaches in use and in development for these cancers, including monoclonal antibodies that target CD20 and inhibitors of FLT3, KIT, JAK2, and B cell receptor signalling.
11 Targeted treatments for cancers of the digestive system (1 day or 2 half-days)
Description: This course provides a description of the faulty genes and proteins that drive colorectal, head and neck, oesophageal, gastric, pancreatic and liver cancer. It also provides an overview of targeted treatment approaches for each of these diseases and the potential of using immunotherapy. The relevant science behind each treatment is explained for a non-scientific, non-specialist audience.
12 Targeted treatments for urological cancers (1 day or 2 half-days)
Description: This course provides a description of the faulty genes and proteins that drive prostate, kidney, bladder and testicular cancer. It also provides an overview of targeted treatment approaches for these diseases, such as hormone therapy, immunotherapy, kinase inhibitors and angiogenesis inhibitors. The relevant science behind each treatment is explained for a non-scientific, non-specialist audience.
13 Targeted treatments for lung cancer (1 day) (can be run as a half-day on NSCLC)
Description: This course describes the faulty genes, pathways and proteins that drive small cell and non-small cell lung cancer. It also explains the scientific rationale behind targeted treatments in use and in development for these diseases, such as EGF-Receptor inhibitors, ALK and ROS1 inhibitors, angiogenesis inhibitors and immunotherapy.
14 Targeted treatments for haematological cancers (1 day)
Description: A more advanced version of course 10. This course describes and explains the unique cellular and genetic features of haematological cancers and covers a diverse range of targeted treatments in development for leukaemia, lymphoma and multiple myeloma. Includes new approaches such as inhibitors of BTK, PI3K-delta and Bcl-2, CAR T cell therapy and PD-1 antibodies.